Distinguishing Axillary Lymphadenopathy after COVID-19 Vaccination from Malignant Lymphadenopathy

Shintaro Yamanaka,Keiko Tanaka,Masao Miyagawa,Teruhito Kido,Shinji Hasebe,Shoichiro Yamamoto,Tomomi Fujii,Kazuto Takeuchi,Yoshihiro Yakushijin

DOI: https://doi.org/10.3390/jcm13123387

IF: 3.9

2024-06-10

Journal of Clinical Medicine

Abstract:Objectives: To study the differences between malignant hypermetabolic axillary lymphadenopathy (MHL) and COVID-19 vaccine-associated axillary hypermetabolic lymphadenopathy (VAHL) using clinical imaging. Methods: A total of 1096 patients underwent Positron Emission Tomography-Computed Tomography (PET-CT) between 1 June 2021 and 30 April 2022 at Ehime University Hospital. In total, 188 patients with axillary lymphadenopathy after the COVID-19 vaccination were evaluated. The patients were classified into three groups such as VAHL (n = 27), MHL (n = 21), and equivocal hypermetabolic axillary lymphadenopathy (EqHL; n = 140). Differences in lymph node (LN) swellings were statistically analyzed using clinical imaging (echography, CT, and 18F-FDG PET). Results: MHL included a higher female population (90.5%) owing to a higher frequency of breast cancer (80.9%). Axillary LNs of MHL did not show any LN fatty hilums (0%); however, those of VAHL and EqHL did (15.8 and 36%, respectively). After the logistic regression analysis of the patients who had axillary lymphadenopathy without any LN fatty hilums, the minor axis length and ellipticity (minor axis/major axis) in the largest axillary LN, SUVmax, and Tissue-to-Background Ratio (TBR) were useful in distinguishing malignant lymphadenopathies. A receiver-operating characteristic (ROC) analysis indicated that a cut-off value of ≥7.3 mm for the axillary LN minor axis (sensitivity: 0.714, specificity: 0.684) and of ≥0.671 for ellipticity (0.667 and 0.773, respectively) in the largest LN with the highest SUVmax and TBR were predictive of MHL. Conclusions: Axillary lymphadenopathy of the minor axis and ellipticity in LN without fatty hilums may be useful to be suspicious for malignancy, even in patients who have received COVID-19 vaccination. Further examinations, such as 18F-FDG PET, are recommended for such patients.

medicine, general & internal

What problem does this paper attempt to address?

The paper attempts to address the issue of differentiating between axillary lymphadenopathy that occurs after receiving a COVID-19 vaccination and malignant lymphadenopathy. Specifically, the researchers aim to distinguish vaccine-induced reactive axillary lymphadenopathy (VAHL) from malignant hypermetabolic axillary lymphadenopathy (MHL) using clinical imaging methods such as ultrasound, CT, and 18F-FDG PET.

### Main Research Objectives:
1. **Distinguish VAHL and MHL**: Identify features that can effectively differentiate these two types of lymphadenopathy by analyzing clinical imaging data.
2. **Determine Diagnostic Indicators**: Establish specific imaging parameter thresholds (e.g., short-axis length, ellipticity, maximum standardized uptake value SUVmax, and tissue background ratio TBR) through statistical analysis to improve diagnostic sensitivity and specificity.

### Research Background:
- **Side Effects of COVID-19 Vaccination**: Some patients develop axillary lymphadenopathy after receiving a COVID-19 vaccination, possibly due to vaccine-induced antigen migration.
- **Clinical Significance**: Differentiating reactive lymphadenopathy from malignant lymphadenopathy is crucial for patients with a history of cancer or suspected cancer, as it directly impacts subsequent treatment decisions.

### Research Methods:
- **Patient Selection**: A retrospective analysis was conducted on 1,096 patients who underwent PET-CT at Ehime University Hospital between June 1, 2021, and April 30, 2022, of which 188 patients had axillary lymphadenopathy.
- **Grouping**: Patients were divided into three groups: VAHL group (27 cases), MHL group (21 cases), and equivocal hypermetabolic axillary lymphadenopathy group (EqHL group, 140 cases).
- **Imaging Analysis**: Detailed analysis of lymph node morphology and metabolic activity was performed using ultrasound, CT, and 18F-FDG PET.

### Main Results:
- **Gender Distribution**: The MHL group had a higher proportion of females (90.5%), mainly due to a higher incidence of breast cancer (80.9%).
- **Presence of Fatty Hilum**: No fatty hilum was found in the lymph nodes of the MHL group (0%), whereas 15.8% and 36% of lymph nodes in the VAHL and EqHL groups, respectively, contained fatty hilum.
- **Imaging Parameters**: Multivariate analysis revealed that short-axis length and ellipticity are important indicators for distinguishing MHL. Specifically, lymph nodes with a short-axis length ≥7.3 mm and ellipticity ≥0.671 are more likely to be malignant.

### Conclusion:
- **Differential Diagnosis**: Short-axis length and ellipticity of axillary lymph nodes can serve as important indicators for distinguishing reactive lymphadenopathy from malignant lymphadenopathy, especially in the absence of a fatty hilum.
- **Further Examination Recommendations**: For patients with these characteristics, further examinations such as 18F-FDG PET are recommended to confirm the diagnosis.

These research findings enable doctors to more accurately determine the nature of axillary lymphadenopathy, thereby providing more appropriate treatment plans for patients.